Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Compass Therapeutics, Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

Compass Therapeutics, Inc.

CMPXNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 22, 2026, Compass Therapeutics, Inc. (the “Company”) issued a press release announcing regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer (“BTC”). A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.…

Filed Sep 22, 2026Accepted Sep 22, 2026, 8:30 AM EDTCIK 1738021Accession 0001171843-26-006162
View company →Permanent SEC source ↗
Share

Company context

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts.

Current securities

CMPXNASDAQ · EQUITY · Current

Recent company filings

  1. 4 filingSep 25, 2026
  2. SCHEDULE 13G/A filingAug 14, 2026
  3. 10-Q filingAug 6, 2026
  4. Results of Operations and Financial ConditionAug 6, 2026
  5. Regulation FD DisclosureJul 1, 2026

Registered securities in this filing

Compass Therapeutics, Inc. · 8-K · Filed 2026-09-22

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.0001 par value per share

Symbol
CMPX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Form8K

Dimensions: Not supplied

Accession 000117184326006162 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 22, 2026, Compass Therapeutics, Inc. (the “Company”) issued a press release announcing regulatory feedback from the FDA relating to tovecimig in patients with biliary tract cancer (“BTC”). A copy of the full press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.